India’s Patent Office revokes Sutent cancer drug patent
14-02-2013
India’s Intellectual Property Appellate Board (IPAB) has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
To request a FREE 2-week trial subscription, use the same link but select the 'trial' option in the dropdown box. NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
ipab, sugen, sutent, pfizer
